Have a feature idea you'd love to see implemented?
Let us know!
IPSC Century Therapeutics Inc
Price (delayed)
$1.46
Market cap
$123.69M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.03
Enterprise value
$132.11M
Highlights
The EPS has increased by 8% since the previous quarter and by 6% year-on-year
The revenue has dropped by 55% year-on-year but it rose by 49% since the previous quarter
Century Therapeutics's gross profit has plunged by 55% YoY but it has increased by 49% from the previous quarter
The debt has grown by 29% year-on-year and by 19% since the previous quarter
Century Therapeutics's net income has decreased by 3.5% YoY
Key stats
What are the main financial stats of IPSC
Market
Valuations
Earnings
Shares outstanding
84.72M
Market cap
$123.69M
Enterprise value
$132.11M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.54
Price to sales (P/S)
58.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
64.69
Revenue
$2.04M
EBIT
-$131.64M
EBITDA
-$117.82M
Free cash flow
-$102.51M
Per share
Balance sheet
Liquidity
EPS
-$2.03
Free cash flow per share
-$1.25
Book value per share
$2.68
Revenue per share
$0.02
TBVPS
$4.61
Total assets
$416.45M
Total liabilities
$194.34M
Debt
$52.71M
Equity
$222.1M
Working capital
$184.32M
Debt to equity
0.24
Current ratio
10.62
Quick ratio
10.4
Net debt/EBITDA
-0.07
Margins
Efficiency
Dividend
EBITDA margin
-5,769.8%
Gross margin
100%
Net margin
-6,434.2%
Operating margin
-7,123%
Return on assets
-34.5%
Return on equity
-65.4%
Return on invested capital
-37.6%
Return on capital employed
-33.1%
Return on sales
-6,446.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IPSC stock price
How has the Century Therapeutics stock price performed over time
Intraday
-4.58%
1 week
-7.01%
1 month
-2.34%
1 year
0.69%
YTD
-56.02%
QTD
-14.62%
Financial performance
How have Century Therapeutics's revenue and profit performed over time
Revenue
$2.04M
Gross profit
$2.04M
Operating income
-$145.45M
Net income
-$131.39M
Gross margin
100%
Net margin
-6,434.2%
Century Therapeutics's operating margin has shrunk by 146% YoY but it has increased by 33% QoQ
The net margin has dropped by 131% year-on-year but it has grown by 34% since the previous quarter
The revenue has dropped by 55% year-on-year but it rose by 49% since the previous quarter
Century Therapeutics's gross profit has plunged by 55% YoY but it has increased by 49% from the previous quarter
Growth
What is Century Therapeutics's growth rate over time
Valuation
What is Century Therapeutics stock price valuation
P/E
N/A
P/B
0.54
P/S
58.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
64.69
The EPS has increased by 8% since the previous quarter and by 6% year-on-year
IPSC's price to book (P/B) is 46% lower than its last 4 quarters average of 1.0
The equity is up by 25% since the previous quarter but it has declined by 10% year-on-year
The revenue has dropped by 55% year-on-year but it rose by 49% since the previous quarter
The price to sales (P/S) is 45% lower than the last 4 quarters average of 107.1
Efficiency
How efficient is Century Therapeutics business performance
The return on sales has dropped by 138% year-on-year but it has increased by 33% since the previous quarter
Century Therapeutics's ROE has decreased by 49% YoY
Century Therapeutics's return on assets has decreased by 27% YoY
The ROIC has contracted by 22% YoY
Dividends
What is IPSC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IPSC.
Financial health
How did Century Therapeutics financials performed over time
Century Therapeutics's total assets is 114% higher than its total liabilities
The current ratio has grown by 26% YoY but it has contracted by 15% from the previous quarter
The quick ratio has increased by 26% year-on-year but it has declined by 14% since the previous quarter
The debt is 76% smaller than the equity
IPSC's debt to equity has soared by 50% year-on-year but it is down by 4% since the previous quarter
The debt has grown by 29% year-on-year and by 19% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.